Angela V. Toms
Intarcia Therapeutics (United States)(US)
Publications by Year
Research Areas
Biochemical and Molecular Research, Enzyme Structure and Function, Cytokine Signaling Pathways and Interactions, Protein Degradation and Inhibitors, Cancer, Hypoxia, and Metabolism
Most-Cited Works
- → The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP(2008)2,085 cited
- → Molecular basis of USP7 inhibition by selective small-molecule inhibitors(2017)450 cited
- → Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase(2016)396 cited
- → Structure and Ubiquitination-Dependent Activation of TANK-Binding Kinase 1(2013)208 cited
- → Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition(2012)162 cited
- → Structure-Based Design and Identification of FT-2102 (Olutasidenib), a Potent Mutant-Selective IDH1 Inhibitor(2020)137 cited
- → Structure of a pseudokinase-domain switch that controls oncogenic activation of Jak kinases(2013)98 cited
- → Structure and function of the interacting domains of Spire and Fmn-family formins(2011)96 cited
- → Structural Characterization of the Regulatory Proteins TenA and TenI from Bacillus subtilis and Identification of TenA as a Thiaminase II,(2005)72 cited
- → Distinct USP25 and USP28 Oligomerization States Regulate Deubiquitinating Activity(2019)72 cited